百诚医药：创新药BIOS-0623-Z4片获得临床试验批准通知书 目前无同靶点且同适应症药品上市
Bio-SBio-S(SZ:301096) Ge Long Hui·2025-09-29 08:33

Core Viewpoint - The company, Baicheng Pharmaceutical, has received clinical trial approval from the National Medical Products Administration (NMPA) for its innovative drug BIOS-0623-Z4, which is aimed at treating cancer pain in adults and is the first of its kind with a non-opioid target mechanism [1] Group 1 - The drug BIOS-0623-Z4 is developed independently by the company and is classified as a Class 1 chemical drug [1] - There are currently no other drugs on the market that share the same target mechanism and indication as BIOS-0623-Z4 [1] - BIOS-0623-Z4 is categorized as an innovative drug that has not been launched domestically or internationally [1]